Results 21 to 30 of about 3,353 (184)

In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of Mycobacterium abscessus

Antibiotics
Background: Mycobacterium abscessus (MABS) is an opportunistic pathogen that causes chronic, difficult-to-treat pulmonary infections, particularly in people with cystic fibrosis (PwCF), leading to rapid lung function decline and increased morbidity and ...
Madeline Sanders, Sun Woo Kim, Aditi Shinde, Danielle Fletcher-Williams, Eric Quach, Paul Beringer   +5 more
doaj   +2 more sources

New Perspectives on Antimicrobial Agents: Imipenem-Relebactam

Antimicrobial Agents and Chemotherapy, 2022
Imipenem (IMI)/cilastatin/relebactam (REL) (I/R) is a novel β-lactam/β-lactamase inhibitor combination with expanded microbiologic activity against carbapenem-resistant non- Morganellaceae Enterobacterales (CR-NME) and difficult-to-treat (DTR) Pseudomonas aeruginosa .
J. Nicholas O’Donnell, Thomas P. Lodise   +1 more
openaire   +3 more sources

Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases [PDF]

Journal of Antimicrobial Chemotherapy, 2020
Abstract Background ESBL- and carbapenemase-producing Pseudomonas aeruginosa are prevalent in, for example, the Middle East, Eastern Europe and Latin America, though rarer elsewhere. Because P. aeruginosa readily mutate to become carbapenem resistant via loss of OprD, isolates producing ESBLs are ...
Shazad Mushtaq, Danièle Meunier, Anna Vickers, Neil Woodford, David M Livermore   +4 more
openaire   +5 more sources

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan

Microbiology Spectrum, 2022
Relebactam is a novel β-lactamase inhibitor of Ambler class A and C β-lactamases that has been developed in combination with imipenem/cilastatin for the treatment of carbapenem-resistant bacterial infections.
Dai Kurihara, Satoru Matsumoto, Naoko Kishi, Yoshikazu Ishii, Masahiko Mori   +4 more
doaj   +3 more sources

Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections [PDF]

Journal of Antimicrobial Chemotherapy, 2019
Imipenem resistance in Pseudomonas aeruginosa most often entails loss of the 'carbapenem-specific' porin OprD; more rarely it reflects acquired carbapenemases. Loss of OprD only confers resistance to imipenem if AmpC β-lactamase is expressed, and we investigated whether this mechanism was overcome by relebactam, a developmental diazabicyclooctane β ...
Carolyne Horner, Shazad Mushtaq, David M Livermore, M Allen, D F J Brown, A P Johnson, C Longshaw, D M Livermore, A P MacGowan, N Woodford   +9 more
openaire   +5 more sources

In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases

Journal of Global Antimicrobial Resistance
Objectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options.
Kengo Hayashi, Masahiro Suzuki, Yoshikazu Ishii, Yasufumi Matsumura, Kazuaki Matsumoto, Sho Saito, Yohei Doi   +6 more
doaj   +2 more sources

In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of Mycobacterium abscessus Complex Isolates

Antibiotics
Background and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many
Alejandro Seoane-Estévez, Pablo Aja-Macaya, Andrea Garcia-Pose, Paula López-Roa, Alba Ruedas-López, Verónica Gonzalez-Galán, Jaime Esteban, Jorge Arca-Suárez, Martín Pampín, Alejandro Beceiro, Marina Oviaño, Germán Bou, on behalf of the GEIM-SEIMC Study Group   +12 more
doaj   +2 more sources

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

Antibiotics, 2023
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin, Sandrine Bernabeu, Cécile Emeraud, Thierry Naas, Delphine Girlich, Agnès B. Jousset, Laurent Dortet   +6 more
doaj   +2 more sources

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

Antibiotics, 2023
Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying blaKPC-2. However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime ...
Krisztina M. Papp-Wallace, Melissa D. Barnes, Magdalena A. Taracila, Christopher R. Bethel, Joseph D. Rutter, Elise T. Zeiser, Katherine Young, Robert A. Bonomo   +7 more
doaj   +2 more sources

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2019
Relebactam is a small‐molecule β‐lactamase inhibitor developed as a fixed‐dose combination with imipenem/cilastatin. The pharmacokinetics of relebactam and imipenem across 10 clinical studies were analyzed using data from adult healthy volunteers and ...
Pratik Bhagunde, Parul Patel, Mallika Lala, Kenny Watson, William Copalu, Ming Xu, Pooja Kulkarni, Katherine Young, Matthew L. Rizk   +8 more
doaj   +3 more sources